|Articles|January 24, 2023
Four Critical Aspects of Clinical Development, Manufacturing, and Analysis for Biologics CDMO
Author(s)Scorpius BioManufacturing
Scorpius BioManufacturing discusses the importance of selecting the right CDMO for your next clinical biologic campaign. They cover what attributes are needed through evaluating analytical integration as well as new technologies to look for that will mitigate risk and speed your drug’s manufacturing timelines,
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
2
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
3
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
4
Industry Experts Probe CNPV Impacts: Part II
5
